ISSN: 2573-4598
Journal of Patient Care

OPEN ACCESS Freely available online

Commentary

Regular Maintenance Therapy on Asthma Patients

Muhammad Hashmi*

Department of Respiratory Diseases, University of Melbourne, Melbourne, Australia

DESCRIPTION

Asthma is a long-term condition that affects children and adults. The airways in the lungs narrow due to inflammation and muscle tightening around the small airways. This causes symptoms of asthma: coughing, wheezing, shortness of breath, chest tightness. These symptoms are intermittent and often worsen at night and during exercise. Other common "triggers" can exacerbate the symptoms of asthma. Triggers vary from person to person, but include viral infections (common colds), dust, smoke, smoke, weather changes, grass and tree pollen, animal fur and feathers, strong soaps and perfumes. Asthma is a condition in which the airways are narrow and swollen, and excess mucus can be produced. This can make breathing difficult and can cause coughing, wheezing when exhaling, and shortness of breath. Asthma is a minor discomfort for some people. For others, it can be a major problem that can interfere with daily activities and lead to life-threatening asthma attacks. Asthma cannot be cured, but its symptoms can be controlled. Asthma often changes over time, so it is important to work with your doctor to track signs and symptoms and adjust treatment as needed. Asthma varies greatly throughout life. Childhood asthma is known for prepubertal male dominance, frequent remissions, and an overall high prevalence with rare mortality. Adult asthma is known for female dominance, rare remissions, and abnormal mortality. Both childhood and adult asthma have variable presentations, which are described herein. Childhood asthma severity is associated with duration of asthma symptoms, medication use, lung function, low socioeconomic status, racial/ethnic minorities, and a neutrophil phenotype.

Adult asthma severity is associated with increased IgE, elevated FeNO, eosinophilia, obesity, smoking, and low socioeconomic status. Adult onset disease is associated with more respiratory symptoms and asthma medication use despite higher pre bronchodilator FEV1/FVC. There is less quiescent disease in adult onset asthma and it appears to be less stable than childhood onset disease with more relapses and less remissions. Although many different factors are associated with an increased risk of asthma, it is often difficult to identify a single direct cause. If other family members also have asthma, they are more likely to have asthma. In particular, asthma in relatives such as parents and siblings is more likely to occur in people with other allergic symptoms such as eczema and rhinitis (hay fever). Urbanization is associated with an increased prevalence of asthma, probably due to multiple lifestyle factors associated with the risk of asthma. These include low birth weight, premature babies, tobacco smoke and other sources of airborne pollution, and viral respiratory infections. Exposure to many pollutants like environmental allergens and irritants is also thought to increase the risk of asthma, including indoor and outdoor air pollution, occupational exposure to house dust mite, mild, chemicals, fumes, or dust. Children and adults who are overweight or obese are at increased risk of developing asthma.

The use of ICSs has been the foundation of asthma remedy for further than 40 times. Studies have reported that ICSs ameliorate all symptoms and physiological abnormalities that characterize asthma and markedly drop the pitfalls of cases passing severe asthma exacerbations, thereby reducing or barring the need for conservation oral corticosteroid remedy [1]. Still, in the 1970s and early 1980s, treatment was limited to cases with moderate to severe asthma owing to enterprises regarding adverse goods associated with regular use of steroids. Because asthma mortality increased in the 1980s, and it was associated with an overuse of SABAs, the benefits of ICSs re-emerged, with studies championing the use of ICSs not only in moderate to severe asthma but also as a conservation remedy in mild asthma [2]. In addition, ICSs are the most effective regulator specifics and have been shown to ameliorate symptom control, tailwind inhibition, and airway hyperresponsiveness [3], ICSs are reduces the threat of exacerbations [4] and asthma mortality [5]. These advancements are due to theiranti-inflammatory parcels, especially their capability to reduce airway eosinophil inflammation. In addition, ICS improves numerous of the pathological abnormalities characteristic of asthma, including structural changes that do in the airway epithelium. Increased subepithelial collagen deposition, showing a drop in airway angiogenesis observed in asthma. Indeed in cases with rare

Correspondence to: Muhammad Hashmi, Department of Respiratory Diseases, University of Melbourne, Melbourne, Australia, E-mail: maham.Hashmi@yahoo.au

Received: 02-Mar-2022, Manuscript No. JPC-22-16136; **Editor assigned:** 04-Mar-2022, Pre QC No. JPC-22-16136(PQ); **Reviewed:** 18-Mar-2022, QC No. JPC-22-16136; **Revised:** 24-Mar-2022, Manuscript No. JPC-22-16136(R); **Published:** 31-Mar-2022, DOI: 10.35248/2573-4598.22.8.187.

Citation: Hashmi M (2022) Regular Maintenance Therapy on Asthma Patients. J Pat Care. 8:187.

symptoms (further than 2 days a month), the choice remains asthma.

This is because cases who are allowed to have mild asthma are at threat of severe asthma exacerbations, which is infrequently fatal. There are 16 asthma cases who cleave to the recommended low- cure ICS but are unfit to achieve optimal asthma control. In these cases, it tends to be necessary to increase the ICS cure if low ICS boluses don't give optimal control. This is despite little substantiation of fresh benefit at high ICS boluses and clear substantiation of an increased threat of side goods. Inhaled corticosteroids these drugs treat asthma over the long term. This means taking it daily to control asthma. They can prevent and relieve swelling of your airways and help your body produce less mucus. They use a device called an inhaler to deliver the drug into the lungs. Another long-term treatment for asthma, these drugs blocks leukotriene's in the body that cause asthma attacks. Take as a tablet once a day. Asthma can be described as a chronic respiratory disease characterized by dyspnoea, wheezing, coughing, and chest tightness. Narrowing and swelling of the airways, and increased mucus production are the major episodes to look for when diagnosing an asthma condition. Physical tests, lung function tests, blood tests, and chest X-ray tests are also used to diagnose asthma. The drugs used to treat asthma in the long term are symptom prophylaxis and symptom managers. Symptom-relieving medications are used for immediate control of symptoms. Occupational factors such as breathing and ingestion of allergens and contaminants, exposure to the cold, exercise, infections, dust and chemicals can be considered risk factors for asthma, and medical professionals prevent and minimize asthma attacks. Patients need to be educated to suppress. Chronic asthma affects a patient's physical, psychological and social well-being.

Anti-inflammatory medicines these medicines reduce swelling and mucus production in your airways. They make it easier for air to enter and exit your lungs. Your healthcare provider may prescribe them to take every day to control or prevent your symptoms. Bronchodilators: These medicines relax the muscles around your airways. The relaxed muscles let the airways move air. It also makes it easier for mucus to pass through the airways. These medications relieve symptoms when they occur. Biological asthma therapy when symptoms persist despite proper inhalation therapy.

REFERENCES

1. Cameron SJ, Cooper EJ, Crompton GK, Hoare MV, Grant IW. Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma. Br Med J. 1973; 4(5886):205-207.
2. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003; 361(9363):1071-1076.
3. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990;142(4):832-836.
4. Szefler S, Weiss S, Tonascia J, Adkinson NF, Bender B, Cherniack R, et al. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000; 343(15):1054-1063.
5. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. N Engl J Med. 2004;169(1):83-88.